Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Method Development to Estimate the Purity of Vesicle Preparations

Published: Thursday, February 28, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
Nanoparticle tracking analysis is used to estimate the purity of vesicle preparations at the Cardiff University School of Medicine.

NanoSight reports on how Nanoparticle Tracking Analysis, NTA, is being used in the development of a method to estimate the purity of vesicle preparations by comparing the ratio of nano-vesicle counts to protein concentration.

This work is reported by Dr Aled Clayton of the School of Medicine at Cardiff University in an original research article published in the Journal of Extracellular Vesicles.

The School of Medicine at Cardiff University is one of the largest medical schools in the United Kingdom, home to over 3000 students and staff.

It is a major international center for teaching and research providing a vibrant community of medical endeavor.

The School is based at the University Hospital of Wales in Cardiff, but is also embedded at other hospital sites in Cardiff including Velindre Cancer Centre.

Dr Aled Clayton and his team are researching the roles of exosomes in modulating tumor immunity and the cancer microenvironment in prostate cancer.

Exosomes are nanometer sized vesicles, produced in abundance by malignant cells but much of their physiological functions are incompletely understood.

Among Dr Clayton's interests are exosomes as possible disease markers, and has been using the NanoSight nanoparticle characterization system as a reliable tool to help develop projects in this field through the analysis of urine/serum from patients. He is keen to develop fluorescent methods with this platform in the future.

Describing his work, Dr Clayton says "as well as our own interests in cancer, we also collaborate with local colleagues interested in diverse conditions (Alzheimer's, cardiac disease, renal disease and others) in which vesicles may play a role. NanoSight's nanoparticle tracking analysis system has been a versatile platform aiding all of these studies."

Continuing, he said "prior to using NTA, there were few other options available. We had made use of electron microscopy but, we have come to rely on NTA as it is a very sensitive and versatile platform, well-suited to daily use."

The work of Dr Clayton and his postdoc, Dr Jason Webber, has recently been published in the Journal of Extracellular Vesicles where they posed the question "How pure are your vesicles?".

In this paper, they proposed a straightforward method to estimate the purity of vesicle preparations by comparing the ratio of nanovesicle counts to protein concentration, using tools including the NanoSight NTA platform and a colorimetric protein assay such as the BCA-assay.

They show this approach is simple enough to apply to every vesicle preparation within a given laboratory, assisting researchers as a routine quality control step.

The paper also proposes that the approach may aid in comparing/standardizing vesicle purity across diverse studies, and may be of particular importance in evaluating vesicular biomarkers.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NanoSight Announce New Appointment
Leading UK scientist, Dr Andrew Shuttleworth, joins NanoSight board as Director of Diagnostic Sciences.
Tuesday, June 26, 2012
Landmark Publication Reports Potential of Exosomes as Biomarkers for Early Disease Detection
NanoSight reports the new publication in one of the most cited peer reviewed journals in nanoscience and nanotechnology, NanoMedicine.
Thursday, July 07, 2011
NanoSight announces interactive webinar on January 27th on Exosome Characterization by Nanoparticle Tracking Analysis
NanoSight, world-leading manufacturers of unique nanoparticle characterization technology, will host an interactive webinar on the subject of exosome characterization by Nanoparticle Tracking Analysis.
Thursday, January 20, 2011
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!